Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
MDGL · Nasdaq · United States · Pharmaceutical Preparations
In shortMADRIGAL PHARMACEUTICALS, INC. is loss-making, burns cash and holds more cash than debt, with revenue growing (+432.1% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -31.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -30.1% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -42.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -31.8% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.01× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.56× | 80/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -13.45× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -1.18 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -19.8% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 1 | 100/100 |
| Revenue growth volatility | – | n/a |
| Operating margin volatility | 173.3% | 0/100 |
Weight in the score: 20%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 180 | 958 |
| Cost of revenue | – | 0 | 0 | 6.2 | – |
| Gross profit | – | 0 | 0 | 174 | – |
| Research & development | 205 | 245 | 272 | 237 | 389 |
| Selling, general & admin | – | 48 | 108 | 435 | 814 |
| Operating income | (242) | (294) | (380) | (498) | (300) |
| Interest expense | 0 | 4 | 13 | 15 | 22 |
| Pre-tax income | – | – | (374) | (466) | (159) |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | (242) | (295) | (374) | (466) | (288) |
| Diluted EPS | −$14.63 | −$17.23 | −$19.99 | −$21.90 | −$12.85 |
| Diluted shares (millions) | 17 | 17 | 19 | 21 | 22 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−1.18 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 30, 2026